Trial Information

Background to the trial:

Patients who are admitted to hospital with pneumonia caused by infection with COVID19 or another bug may have difficulties breathing. Many need oxygen and some need help to breathe (put on a ventilator) before they get better. However, a small number of people don’t get better. Their lungs can over-react to the infection and become inflamed. Over time their lungs may gradually become more and more damaged.

Overview of the trial drug:

A company in the UK, Evgen Pharma, have developed a drug called SFX-01 which we think might help people with pneumonia. The drug isn’t licenced for doctors to prescribe yet but the company has done trials using the drug to check that it is safe. We think that SFX-01 may help people with pneumonia by reducing the amount of inflammation and damage in their lungs. We want to know if taking SFX-01 shortens your time in hospital. We also want to find out if you’re less likely to need oxygen for a long period or put on a ventilator and if you’re more likely to recover.

Trial population:

The trial will recruit patients who have been hospitalised with pneumonia or suspected COVID-19. This trial aims to recruit 300 patients from hospitals in the UK.

Trial treatment:

All participants taking part in the trial will receive the usual standard of care. Participants will be randomised (by chance) to receive either the trial drug (SFX-01) or a placebo. Each participant will take either one SFX-01 capsule or one placebo capsule every day for 14 days.

Trial aims:

We think that SFX-01 may help people with pneumonia by reducing the amount of inflammation and damage in their lungs. We want to know if taking SFX-01 shortens your time in hospital. We also want to find out if you’re less likely to need oxygen for a long period or put on a ventilator and if you’re more likely to recover.